MX2021003030A - Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. - Google Patents
Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.Info
- Publication number
- MX2021003030A MX2021003030A MX2021003030A MX2021003030A MX2021003030A MX 2021003030 A MX2021003030 A MX 2021003030A MX 2021003030 A MX2021003030 A MX 2021003030A MX 2021003030 A MX2021003030 A MX 2021003030A MX 2021003030 A MX2021003030 A MX 2021003030A
- Authority
- MX
- Mexico
- Prior art keywords
- joint
- treatment
- pharmaceutical compositions
- suitable pharmaceutical
- joint pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731941P | 2018-09-16 | 2018-09-16 | |
| PCT/US2019/051247 WO2020056399A1 (en) | 2018-09-16 | 2019-09-16 | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003030A true MX2021003030A (es) | 2021-05-27 |
Family
ID=68084954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003030A MX2021003030A (es) | 2018-09-16 | 2019-09-16 | Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12208104B2 (enExample) |
| EP (1) | EP3849522A1 (enExample) |
| JP (1) | JP7634476B2 (enExample) |
| KR (1) | KR20210060559A (enExample) |
| CN (1) | CN112702993A (enExample) |
| AU (1) | AU2019339528B2 (enExample) |
| BR (1) | BR112021004880A2 (enExample) |
| CA (1) | CA3112234A1 (enExample) |
| CL (1) | CL2021000627A1 (enExample) |
| IL (1) | IL281513B1 (enExample) |
| MX (1) | MX2021003030A (enExample) |
| SG (1) | SG11202102400PA (enExample) |
| TW (1) | TWI843751B (enExample) |
| WO (1) | WO2020056399A1 (enExample) |
| ZA (1) | ZA202101688B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023537474A (ja) | 2020-08-05 | 2023-09-01 | ティーエルシー バイオファーマシューティカルズ、インク． | 疼痛制御のための関節内コルチコステロイドの医薬組成物 |
| EP4706666A1 (en) * | 2023-05-05 | 2026-03-11 | Xiangya Hospital, Central South University | Use of magnesium hydroxide in preparation of drug for treating arthralgia |
| IL327816A (en) * | 2023-11-03 | 2026-06-01 | Taiwan Liposome Co Ltd | Liposomal composition of intra-articular corticosteroid for pain control |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050152962A1 (en) * | 2002-06-12 | 2005-07-14 | Metselaar Josbert M. | Composition for treatment of inflammatory disorders |
| EP1371362A1 (en) * | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
| AU2013216861B2 (en) | 2012-02-10 | 2017-05-18 | Tlc Biopharmaceuticals, Inc | Pharmaceutical compositions to reduce complications of ocular steroid |
| BR112015000174A2 (pt) * | 2012-07-05 | 2017-06-27 | Taiwan Liposome Co Ltd | método para o tratamento da artrite |
-
2019
- 2019-09-16 IL IL281513A patent/IL281513B1/en unknown
- 2019-09-16 AU AU2019339528A patent/AU2019339528B2/en active Active
- 2019-09-16 WO PCT/US2019/051247 patent/WO2020056399A1/en not_active Ceased
- 2019-09-16 BR BR112021004880-4A patent/BR112021004880A2/pt unknown
- 2019-09-16 SG SG11202102400PA patent/SG11202102400PA/en unknown
- 2019-09-16 MX MX2021003030A patent/MX2021003030A/es unknown
- 2019-09-16 JP JP2021511641A patent/JP7634476B2/ja active Active
- 2019-09-16 CA CA3112234A patent/CA3112234A1/en active Pending
- 2019-09-16 CN CN201980059773.8A patent/CN112702993A/zh active Pending
- 2019-09-16 EP EP19779658.4A patent/EP3849522A1/en active Pending
- 2019-09-16 US US17/272,387 patent/US12208104B2/en active Active
- 2019-09-16 TW TW108133237A patent/TWI843751B/zh active
- 2019-09-16 KR KR1020217011328A patent/KR20210060559A/ko not_active Ceased
-
2021
- 2021-03-12 ZA ZA2021/01688A patent/ZA202101688B/en unknown
- 2021-03-15 CL CL2021000627A patent/CL2021000627A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL281513B1 (en) | 2026-07-01 |
| IL281513A (en) | 2021-04-29 |
| AU2019339528A1 (en) | 2021-04-15 |
| AU2019339528B2 (en) | 2025-01-30 |
| ZA202101688B (en) | 2024-06-26 |
| TW202023569A (zh) | 2020-07-01 |
| WO2020056399A1 (en) | 2020-03-19 |
| EP3849522A1 (en) | 2021-07-21 |
| TWI843751B (zh) | 2024-06-01 |
| KR20210060559A (ko) | 2021-05-26 |
| US12208104B2 (en) | 2025-01-28 |
| CA3112234A1 (en) | 2020-03-19 |
| US20210338688A1 (en) | 2021-11-04 |
| CN112702993A (zh) | 2021-04-23 |
| JP2022500364A (ja) | 2022-01-04 |
| SG11202102400PA (en) | 2021-04-29 |
| BR112021004880A2 (pt) | 2021-06-01 |
| JP7634476B2 (ja) | 2025-02-21 |
| CL2021000627A1 (es) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| MX2021006575A (es) | Composiciones y metodos para el tratamiento de trastornos del higado. | |
| MX2025004156A (es) | Composiciones topicas para el alivio del dolor. | |
| CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
| AR065580A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
| AR132497A1 (es) | Combinación de obicetrapib amorfo e inhibidor de sglt2 | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| PH12021553056A1 (en) | Modified release formulations and uses thereof | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| AR048718A1 (es) | Uso de formulaciones de meloxicam en medicina veterinaria | |
| PA8627601A1 (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos | |
| CL2022001323A1 (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x | |
| AR127966A1 (es) | Formulaciones tópicas de inhibidores de pi3k-delta | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| MX2021013347A (es) | Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina. | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| PE20252784A1 (es) | Composiciones y metodos para administrar paltusotina a pacientes con insuficiencia hepatica | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico | |
| MX2020009645A (es) | Inhibidores de secrecion de proteinas basados en triazaciclododecansulfonamida ("tcd"). | |
| CO2018009584A2 (es) | Composición anestésica tópica |